Welcome to our dedicated page for Passage Bio news (Ticker: PASG), a resource for investors and traders seeking the latest updates and insights on Passage Bio stock.
Passage Bio, Inc. develops clinical-stage genetic medicines for neurodegenerative diseases, with news centered on PBFT02 and the upliFT-D study in frontotemporal dementia. Company updates commonly address safety and biomarker data, progranulin and neurofilament light-chain measures, patient groups involving FTD-GRN and FTD-C9orf72, and FDA interactions tied to potential registrational development.
Recurring announcements also cover periodic financial results, corporate presentations, investor conference participation, manufacturing comparability work, and strategic or operating updates that affect the company's development plans and expense profile.
Passage Bio (Nasdaq: PASG), a clinical-stage genetic medicines company, announced that CEO Bruce Goldsmith, Ph.D., will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 10:30 a.m. ET. The event will be held virtually, and a live webcast will be accessible on the company’s website, with a replay available for 30 days post-event. Passage Bio focuses on transformative therapies for central nervous system disorders and collaborates with the University of Pennsylvania’s Gene Therapy Program to enhance its gene therapy pipeline.
Passage Bio (Nasdaq: PASG) disclosed that the Independent Data Monitoring Committee recommends advancing to additional cohorts in the Imagine-1 clinical study, targeting pediatric patients with GM1 Gangliosidosis. The Phase 1/2 study demonstrated a positive safety profile with no serious adverse events, while beta-galactosidase enzyme activity significantly increased in cerebrospinal fluid and serum. Cohorts 2 and 3 are now being recruited following encouraging interim data. Results will be presented at the 18th Annual WORLD Symposium on February 11, 2022.
Passage Bio, Inc. (Nasdaq: PASG) has exercised two additional options with the University of Pennsylvania's Gene Therapy Program, focusing on Huntington's and Canavan diseases. The company plans to report initial safety and biomarker data from its Phase 1/2 trial for PBGM01 by year-end 2021 and expects to begin dosing patients for trials targeting frontotemporal dementia and Krabbe disease in early 2022. The strategic partnership enhances Passage Bio's pipeline, now including three clinical-stage assets and six additional programs, aimed at addressing significant unmet needs in CNS disorders.
Passage Bio (Nasdaq: PASG) announced the granting of an inducement stock option to a new employee, comprising 130,000 shares at an exercise price of $8.50, equal to the stock's closing price on November 15, 2021. The option will vest over four years with the first 25% vesting after one year, followed by monthly installments. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's strategy to attract talent while advancing its mission in developing genetic therapies for CNS disorders.
Passage Bio, Inc. (Nasdaq: PASG) has announced that CEO Bruce Goldsmith will participate in a fireside chat at the Guggenheim 3rd Annual Neuro/Immunology Conference on November 16, 2021, at 3:00 p.m. ET. This virtual event will feature discussions on the company's advancements in genetic therapies for central nervous system disorders. A live webcast will be available on Passage Bio's website, with a replay accessible for 30 days post-event. The company aims to provide transformative genetic medicines and has established a collaboration with the University of Pennsylvania's Gene Therapy Program.
Passage Bio (NASDAQ: PASG) reported Q3 2021 financial results, with cash reserves of $354.4 million, sufficient for operations for at least 24 months. The company is advancing its Phase 1/2 trials for PBGM01, PBFT02, and PBKR03, targeting CNS disorders, with initial safety and biomarker data expected by 4Q21. R&D expenses rose to $26.6 million, and G&A expenses increased to $15.0 million, contributing to a net loss of $46.9 million. Management remains focused on executing their clinical programs and anticipates new data releases in early 2022.
Passage Bio (NASDAQ: PASG) will host a conference call on November 4, 2021, at 8:30 a.m. ET to discuss its third quarter 2021 financial results and recent business highlights. Investors can join by calling 833-528-0605 (domestic) or 830-221-9711 (international) using conference ID 2985094, or watch a live webcast on the company's website. The event will be archived for 30 days post-event. The company focuses on gene therapies for central nervous system disorders and collaborates with the University of Pennsylvania's Gene Therapy Program to advance its pipeline.
Passage Bio, Inc. (NASDAQ: PASG) announced participation in two conferences in October 2021. The first event is the Chardan 5th Annual Genetic Medicines Conference on October 4, featuring CEO Bruce Goldsmith in a virtual fireside chat at 9 a.m. ET. The second event is the Alliance for Regenerative Medicine: Cell & Gene Meeting on the Mesa on October 12, with COO Jill Quigley presenting at 5:45 p.m. ET. Live webcasts and replays will be available on the company’s website, enhancing investor engagement.
Passage Bio (Nasdaq: PASG) announced the granting of inducement awards to eight new employees, comprising options to purchase a total of 72,000 shares. The options, priced at $11.50 per share, match the closing stock price on September 15, 2021. These inducement options will vest over four years, with 25% vesting after one year and the rest in monthly installments. This award follows Nasdaq's Rule 5635(c)(4). Passage Bio focuses on developing genetic therapies for central nervous system disorders.
Passage Bio (Nasdaq: PASG) announced the appointment of Maxine Gowen, Ph.D. as chairwoman of the board of directors, effective August 31. With over 30 years in the biopharmaceutical industry, Dr. Gowen, who joined the board in February 2021, brings extensive experience to the role. She aims to advance Passage Bio's mission to develop therapies for central nervous system disorders following the unexpected passing of former chairman Dr. Tadataka Yamada. Dr. Gowen emphasizes the company's potential in creating innovative genetic medicines.